A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients With Recurrent Glioblastoma
Latest Information Update: 26 Aug 2024
At a glance
- Drugs NMS 293 (Primary) ; Temozolomide (Primary) ; Lomustine
- Indications Astrocytoma; Glioblastoma; Oligodendroglioma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Nerviano Medical Sciences
- 13 Mar 2024 Planned number of patients changed from 125 to 150.
- 12 Oct 2023 Results (n=21) presented in a Nerviano Medical Sciences media release.
- 12 Oct 2023 According to a Nerviano Medical Sciences media release, initial results data from this trial presented at the AACR-NCI-EORTC 2023 Annual Meeting in Boston, Massachusetts.